Not each future unicorn begins with noise and hype. Some are constructed beneath the roof quietly with years of analysis, testing, and real-world deployment.
Throughout Europe, a bunch of startups is doing precisely that. They aren’t chasing short-term developments. As an alternative, they’re engaged on foundational know-how embedded inside important techniques. These corporations function in environments the place errors are pricey and expectations are excessive, together with power grids, defence techniques, hospitals, monetary establishments, and extra.
From clear power technology and embedded cybersecurity to robotics, medical units, and compliance software program, their work helps the infrastructure on which economies rely. This offers them clearer demand, longer contracts, and extra predictable progress as soon as adoption begins.
Looking forward to 2026, many of those startups are transferring from improvement to deployment. Some are getting into new markets, forming main partnerships, or preparing for bigger funding rounds. Whereas they could not but be valued as unicorns, they’re shut.
On this article, now we have compiled a listing of 10 European soonicorns to look at in 2026.
Proxima Fusion (Germany)
Founder/s:
Based yr: 2023
Valuation: $715M
Proxima Fusion, a Munich-based fusion power firm based in April 2023, develops next-generation fusion energy crops utilizing quasi-isodynamic (QI) stellarators. The corporate was established by Dr Francesco Sciortino, Dr Lucio Milanese, Dr Jorrit Lion, Jonathan Schilling, and Martin Kubie, former scientists and engineers from the Max Planck Institute for Plasma Physics, the Massachusetts Institute of Expertise, and X Growth (previously Google-X).
Proxima is building a pipeline of stellarator-based fusion technology to achieve commercial fusion power generation. The company’s lead project, the Alpha demo stellarator, is scheduled to begin operations and achieve first plasma in 2031.
In February 2025, Proxima presented a concept for a commercial fusion power plant, Stellaris, that integrates advances in superconducting magnets and computational optimisation to improve plasma stability and confinement.
In June 2025, Proxima completed a €130 million Series A funding round co-led by Cherry Ventures and Balderton Capital, with participation from Lightspeed Enterprise Companions, UVC Companions, and others. In September 2025, the corporate extended its Series A with an extra €15 million from Italian state fund CDP Venture Capital, the European Innovation Council Fund, and Brevan Howard, bringing complete funding to €200 million.
Hemab Therapeutics (Denmark)
Founder/s: Dr Johan Faber, Dr Søren Bjørn, Benny Sørensen
Based yr: 2019
Valuation: $628—942M
Hemab Therapeutics, a Copenhagen and Cambridge-based clinical-stage biopharmaceutical firm based in 2019, develops prophylactic therapies for severe, underserved bleeding and thrombotic issues. The corporate was established by Dr Johan Faber and Dr Søren Bjørn, with Benny Sørensen serving as CEO and co-founder.
Hemab builds a pipeline of monoclonal and bispecific antibody-based therapeutics to forestall, relatively than merely handle, bleeding issues. The corporate’s lead program, sutacimig (previously HMB-001), is a first-in-class prophylactic bispecific antibody that has accomplished Part 2 testing in Glanzmann thrombasthenia, demonstrating larger than 50% discount in yearly bleeds, with registration research deliberate for 2026.
A second candidate, HMB-002, is a monovalent antibody in Part 1/2 improvement for von Willebrand illness, concentrating on the underlying pathophysiology by rising each von Willebrand Issue and Issue VIII ranges. A 3rd program, HMB-003, is anticipated to advance into scientific improvement within the first half of 2026.
In October 2025, Hemab completed a $157 million Series C financing round led by Sofinnova Partners, with participation from Avoro Capital Advisors, Novo Holdings, RA Capital Administration, Entry Biotechnology, Deep Observe Capital, HealthCap, Invus, Maj Make investments Fairness, and Rock Springs Capital.
Exeger (Sweden)
Founder/s: Giovanni Fili
Founded year: 2009
Valuation: $605M
Exeger, a Stockholm-based deep-tech company founded in 2009, develops and manufactures Powerfoyle. This next-generation flexible solar cell technology converts both artificial and natural light into electrical energy for consumer electronics and everyday devices.
The company was founded by Giovanni Fili, who recognised the business potential of dye-sensitised photo voltaic cells (DSSCs) and established the corporate to make the know-how viable for mass manufacturing. Dr Henrik Lindström joined in 2009 as Chief Expertise Officer to steer the event of a superconducting electrode materials with 1,000 occasions the conductivity of typical supplies, enabling free-form printing of huge, customizable photo voltaic cells.
Exeger is building a pipeline of Powerfoyle-based products to replace disposable batteries in electronic devices while reducing reliance on critical raw materials. The company’s technology is unique in its ability to work efficiently in both outdoor sunlight and indoor artificial lighting, making it suitable for seamless integration into consumer electronics, including wireless headphones, computer mice and keyboards, hearing protectors, and automotive toll payment systems.
In November 2025, Exeger raised at least SEK 160 million (approximately €15 million) through a directed share issue, alongside a SEK 110.42 million rights issue, with participation from existing investors, including Stena Sessan and other stakeholders.
FINN
Founder/s: Maximilian Wühr, Jens Kegelmann, Max J. Meier, Fabian Siegel
Founded year: 2019
Valuation: $603M
FINN, a Munich-based mobility startup founded in 2019, develops a car subscription platform that enables customers to drive vehicles without long-term commitments through an all-inclusive, technology-enabled service model.
The company was founded by Maximilian Wühr (CEO and co-founder), Jens Kegelmann (Chief Product Officer and co-founder), Max J. Meier (former CEO and co-founder), and Fabian Siegel (co-founder), who reimagined automobile possession and leasing by constructing a direct-to-consumer subscription service that mixes a curated automobile choice with complete logistics, insurance coverage, upkeep, and administrative dealing with.
FINN builds a frictionless mobility platform that eliminates inefficiencies in the traditional automotive industry through proprietary technology and operational automation. The company operates a B2B fleet business serving corporate clients, which now accounts for approximately 50% of Annual Recurring Revenue.
In January 2024, FINN completed a €100 million Series C funding round led by Planet First Partners, with participation from HV Capital, Korelya Capital, UVC Partners, White Star Capital, and Picus Capital. The spherical valued the corporate at over $600 million and positions FINN as a frontrunner within the electrical mobility transition.
Distalmotion
Founder/s: EPFL Robotics Lab (spin-off)
Based yr: 2011
Valuation: $600—900M
Distalmotion, a Lausanne-based medical gadget firm based in 2012, develops and commercialises Dexter, a next-generation surgical robotic designed to democratize entry to minimally invasive robotic surgical procedure throughout various care settings.
The corporate originated as a spin-off from the Robotics Methods Laboratory of the Swiss Federal Institute of Expertise in Lausanne (EPFL), rising from a doctoral thesis centered on reimagining surgical robotics to attain real scientific relevance and allow broad affected person entry to high-quality minimally invasive care.
Distalmotion develops a soft-tissue surgical platform that simplifies robotic surgical procedure by way of a hybrid structure, enabling surgeons to modify between robotic and laparoscopic modalities throughout procedures seamlessly. The corporate’s lead product, Dexter, is distinguished by its skill to maintain surgeons sterile and in direct proximity to sufferers whereas enabling full surgical management. The system contains a totally wristed, single-use instrument set, enabling versatile enterprise fashions, together with conventional CapEx gross sales and modern pay-per-use preparations tailor-made to the rising ambulatory surgical procedure centre (ASC) market.
In November 2025, Distalmotion accomplished a $150 million Collection G financing spherical led by Revival Healthcare Capital with participation from current buyers, bringing the corporate’s complete funding to over $240 million.
Perpetual Subsequent (The Netherlands)
Founder/s: Martijn van Rheenen
Based yr: 2019
Valuation: $592M
Perpetual Subsequent, an Amsterdam-based local weather know-how firm based in 2019, develops and operates large-scale manufacturing amenities that convert low-grade natural waste streams and residues into high-value renewable commodities, together with biomethanol, biochar, inexperienced gases, and inexperienced hydrogen.
The corporate was established by Martijn van Rheenen, founder and investor at Momentum Capital, by way of a strategic merger of a number of climate-technology portfolio corporations to create a unified, scalable platform for carbon removing and circular-economy options.
Perpetual Subsequent builds a standardised know-how blueprint for upgrading natural waste into premium commodities whereas capturing carbon worth that will in any other case enter the ambiance as CO2. The corporate’s lead product portfolio consists of biomethanol manufacturing amenities designed to course of roughly 220,000 tons yearly per website, utilizing a proprietary blueprint developed in collaboration with Air Liquide and engineering agency Fluor, and a standardised mannequin that permits speedy serial scale-up throughout a number of geographies.
In November 2025, Perpetual Subsequent’s Collection B financing closed at roughly €200 million, with complete capital commitments from Momentum International Ventures by way of its subsidiaries, which maintain a strategic majority stake within the firm.
Azafaros (The Netherlands)
Founder/s: Prof. Hans Aerts, Prof. Hermen Overkleeft, Prof. Stan van Boeckel
Based yr: 2018
Valuation: $581—871M
Azafaros, a Netherlands-based clinical-stage biopharmaceutical firm based in 2018, develops disease-modifying therapies for uncommon lysosomal storage issues, with operations in Leiden, the Netherlands and Basel, Switzerland.
The corporate was established by BioGeneration Ventures (BGV) and is constructed on a long time of scientific discovery by Prof. Hans Aerts, Prof. Hermen Overkleeft, and Prof. Stan van Boeckel. The corporate is at present led by Stefano Portolano, M.D., as Chief Govt Officer.
Azafaros builds a pipeline of oral small molecule therapeutics with disease-modifying potential targeting life-threatening neurological lysosomal storage disorders for which no effective treatments currently exist. The company’s lead asset, nizubaglustat (AZ-3102), is a first-in-class, dual-acting azasugar molecule with unique brain penetration that simultaneously reduces toxic glycolipid accumulation and modulates autophagy through a novel dual mode of action.
Nizubaglustat is being developed to treat Niemann-Pick disease Type C (NPC), GM1 gangliosidosis, and GM2 gangliosidosis (including Tay-Sachs and Sandhoff diseases). The FDA has granted Orphan Drug Designation, Rare Pediatric Disease Designation, and Fast Track Designation for nizubaglustat for NPC and GM1/GM2 gangliosidoses. In contrast, the European Medicines Agency has granted Orphan Medicinal Product Designation for GM1 and GM2 gangliosidoses.
In May 2025, Azafaros completed an oversubscribed €132 million Series B financing round led by Jeito Capital and co-led by Forbion Development, with extra participation from Seroba, Pictet Group, Schroders Capital, and BioGeneration Ventures.
AAVantgarde Bio (Italy)
Founder/s: Professor Alberto Auricchio
Based yr: 2021
Valuation: $564—846M
AAVantgarde Bio, a Milan-based clinical-stage biopharmaceutical firm based in 2021, develops next-generation gene therapies for inherited retinal illnesses utilizing proprietary adeno-associated viral (AAV) vector platforms designed to beat gene supply limitations. The corporate was co-founded by Professor Alberto Auricchio, in collaboration with the Telethon Basis and with help from Sofinnova Companions by way of the Sofinnova-Telethon Fund.
AAVantgarde builds two platforms, the Twin Hybrid and AAV-Intein techniques, that overcome the restrictions of typical AAV vectors, which have a cargo capability of 4.7 kilobases, stopping them from delivering giant therapeutic genes. The corporate’s modern strategy makes use of twin AAV vectors that cut up giant genes into two halves, package deal every right into a separate AAV vector, and allow reassembly inside goal cells to provide the full-length, practical gene.
In November 2025, AAVantgarde accomplished a $141 million Collection B financing spherical led by Schroders Capital, Atlas Enterprise, and Forbion, with participation from Amgen Ventures, Athos Capital, CDP Enterprise Capital, Columbia IMC, Neva SGR, Sixty Diploma Capital, XGen Enterprise, and Willett Advisors, in addition to Longwood Fund and Sofinnova Companions.
Numab Therapeutics (Switzerland)
Founder/s:
Based yr: 2021
Valuation: $550M
Numab Therapeutics, a Horgen and Zurich-area-based clinical-stage biopharmaceutical firm based in 2011, develops next-generation multi-specific antibody therapeutics for most cancers immunotherapy and inflammatory illnesses utilizing proprietary platform applied sciences.
The corporate was based by Dr David Urech, PhD, as a co-founder and Chief Scientific Officer, who served as Chief Govt Officer from 2018 by way of September 2025, constructing Numab into a frontrunner in modern multi-specific antibody drug design.
Numab builds a reproducible, plug-and-play therapeutic design platform centred on two applied sciences, Lambda-Cap™ and MATCH™, that allow the rational engineering of multi-specific antibodies with tailor-made pharmacokinetic properties, targetability, and therapeutic profiles. The platform overcomes historic obstacles in drug discovery by growing first-in-class and best-in-class medicines that maximise affected person profit by way of novel therapeutic methods.
The corporate’s lead immuno-oncology program, NM21-1480 (now in improvement), combines PD-L1 blockade with tumour-localised 4-1BB co-stimulation in a single molecule to steadiness potent anti-tumour immunity with a beneficial security profile in stable tumours.
In January 2025, Numab accomplished a CHF 50 million (roughly $55 million) Collection C top-up financing spherical, bringing the full Collection C to CHF 180 million and considerably increasing the corporate’s capital base to advance its pipeline of multi-specific scientific and preclinical antibodies.
Splice Bio
Founder/s: Dr Miquel Vila-Perelló and Dr Silvia Frutos, PhD
Based yr: 2021
Valuation: $540—810M
Splice Bio (previously ProteoDesign), a Barcelona-based clinical-stage genetic medicines firm initially based in 2014 and rebranded in 2020, develops next-generation gene therapies utilizing a proprietary Protein Splicing platform primarily based on engineered inteins to beat the scale limitations of conventional gene supply techniques.
The corporate was based by Dr Miquel Vila-Perelló, PhD (CEO and co-founder) and Dr Silvia Frutos, PhD (Chief Expertise Officer and co-founder), each scientists who pioneered protein splicing and intein engineering analysis over twenty years at Princeton College’s Muir Lab and different main establishments.
Splice Bio is growing a therapeutic strategy that makes use of engineered cut up inteins to ship giant genes that exceed the cargo capability of conventional adeno-associated viral (AAV) vectors (roughly 4.7 kilobases). By splitting giant genes into two items and packaging every in separate AAV vectors, the inteins catalyse extremely environment friendly protein trans-splicing in vivo to reconstitute the full-length, practical therapeutic protein straight in affected person cells.
In June 2025, Splice Bio accomplished a $135 million Collection B financing spherical co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund and all current buyers, together with New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Enterprise Fund, and Asabys Companions.
